Menu
Search
|

Menu

Close
X

AcelRx Pharmaceuticals Inc ACRX.OQ (NASDAQ Stock Exchange Global Market)

3.35 USD
-- (--)
As of Mar 20
chart
Previous Close 3.35
Open --
Volume --
3m Avg Volume 450,258
Today’s High --
Today’s Low --
52 Week High 5.05
52 Week Low 2.00
Shares Outstanding (mil) 78.76
Market Capitalization (mil) 263.84
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
8
FY16
17
EPS (USD)
FY18
-0.639
FY17
-0.431
FY16
-0.952
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.80
Price to Sales (TTM)
vs sector
115.82
8.99
Price to Book (MRQ)
vs sector
--
4.66
Price to Cash Flow (TTM)
vs sector
--
40.60
Total Debt to Equity (MRQ)
vs sector
--
17.49
LT Debt to Equity (MRQ)
vs sector
--
13.83
Return on Investment (TTM)
vs sector
-15.82
12.11
Return on Equity (TTM)
vs sector
--
13.22

EXECUTIVE LEADERSHIP

Adrian Adams
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Richard King
President, Since 2015
Salary: $490,000.00
Bonus: $91,875.00
Vincent Angotti
Chief Executive Officer, Since 2017
Salary: $493,461.00
Bonus: $164,340.00
Raffi Asadorian
Chief Financial Officer, Since 2017
Salary: $150,000.00
Bonus: $34,200.00
Pamela Palmer
Chief Medical Officer, Director, Since 2005
Salary: $421,000.00
Bonus: $104,987.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

351 Galveston Dr
REDWOOD CITY   CA   94063-4736

Phone: +1650.2163500

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

SPONSORED STORIES